Secrecy shrouds taxpayer-supported research [New Jersey]
By North Jersey Media Group,
North Jersey Media Group
| 06. 19. 2005
The church organist filled out a disclosure form.
So did the part-time bartender.
Both were required to disclose any jobs other than their positions with Rowan University, a state school.
Dr. Raphael Mannino, too, has employment beyond his public-sector position as an associate professor at the University of Medicine and Dentistry of New Jersey. He's an executive with one biotech start-up company and a paid board member of another.
But there's no disclosure form on file for him with the state Executive Commission on Ethical Standards. And there are none on file for anyone else at UMDNJ, or at either of the state's two other research universities.
Mannino is just one example of a hole in the system that ensures public interests, not private ones, are served by those involved in taxpayer-supported medical research.
Secrecy is important to the biotech industry, in both its business and research incarnations. After all, this is a world where the sole ownership of ideas is the basis of profits.
The picture is more complicated on the public side of the biotechnology partnership.
In particular...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...